Phase III
Topline results from the Phase III SURPASS-1 trial show that a 40-week treatment with Eli Lilly’s tirzepatide led to significant reductions in A1c and body weight in adults with type 2 diabetes.
AbbVie announced that its Phase III induction study, U-ACHIEVE, of Rinvoq (upadacitinib) in moderate to severe ulcerative colitis, hit the primary endpoint of clinical remission at week 8.
The COVID-19 vaccine under development by China’s Sinopharm is showing efficacy of 86%, health authorities from the United Arab Emirates reported this morning.
AstraZeneca and the University of Oxford published an interim analysis of their four Phase III clinical trials of AZD1222, their COVID-19 vaccine.
Constellation Pharmaceuticals announced on Sunday that it has received preliminary data from its Phase II MANIFEST and Phase III MANIFEST-2 clinical trials involving CPI-0610 for myelofibrosis.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 8, 2020.
A dual treatment approach consisting of gemcitabine combined with AB Science’s masitinib was associated with significant increases in survival among patients with pancreatic cancer and pain.
The four promising treatments showed no effect on reducing mortality in ongoing Solidarity Trial.
It was a moderately busy week for clinical trial news, with some important reports coming out about COVID-19 vaccines. Here’s a look.
While promising, the study showed no difference between this combination regimen and physician’s choice of topotecan or cyclophosphamide/doxorubicin/vincristine (CAV) in terms of overall survival (OS).
PRESS RELEASES